Estradiol Patch Dosage Chart: Every Strength, Equivalent, and Conversion You Need

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 10 sources cited

Key Takeaways

• Estradiol transdermal patches come in five common strengths: 0.025, 0.0375, 0.05, 0.075, and 0.1 mg per day.
• Most providers start at 0.025 mg/day or 0.0375 mg/day and titrate up based on symptom response over 4-8 weeks.
• Twice-weekly patches (Vivelle-Dot, Minivelle, Climara Pro) are changed every 3-4 days; once-weekly patches (Climara) are changed every 7 days.
• Transdermal estradiol bypasses first-pass liver metabolism, which lowers VTE and stroke risk compared with oral estrogen (Canonico et al., BMJ 2010).
• 0.05 mg/day patch produces serum estradiol levels roughly equivalent to 1 mg oral estradiol or 0.625 mg conjugated estrogens.

Direct answer (40-60 words)

Estradiol transdermal patches are dosed in mg per day delivered through the skin. Common strengths are 0.025, 0.0375, 0.05, 0.075, and 0.1 mg/day. Starting dose is usually 0.025 or 0.0375 mg/day. Standard maintenance for most menopausal hot flash management is 0.05 mg/day, applied twice weekly or once weekly depending on the brand.

Table of contents

1. The 30-second answer
2. Standard estradiol patch dosing chart
3. Twice-weekly vs once-weekly application schedules
4. How to convert from oral estradiol to a patch
5. How to convert between patch strengths
6. Starting dose and titration schedule
7. Maximum effective dose
8. Patches for primary ovarian insufficiency vs natural menopause
9. Application sites and rotation
10. When to add progesterone
11. FAQ
12. Sources
13. Footer disclaimers

Standard estradiol patch dosing chart

The five FDA-approved estradiol patch strengths and their typical use cases:

Patch strength	Daily delivery	Common brands	Typical use
0.025 mg/day	25 mcg	Vivelle-Dot, Minivelle, Climara	Starting dose, mild symptoms, perimenopause
0.0375 mg/day	37.5 mcg	Vivelle-Dot, Minivelle	Starting dose for moderate symptoms
0.05 mg/day	50 mcg	Vivelle-Dot, Minivelle, Climara, Estradot	Standard maintenance dose
0.075 mg/day	75 mcg	Vivelle-Dot, Minivelle, Climara	Refractory hot flashes, surgical menopause
0.1 mg/day	100 mcg	Vivelle-Dot, Minivelle, Climara	Maximum standard dose, primary ovarian insufficiency

The numbers refer to milligrams of estradiol delivered per 24 hours through the skin, not the total estradiol content of the patch. A 0.05 mg/day patch worn for 3.5 days delivers about 0.175 mg of estradiol total over its application period.

Generic transdermal estradiol patches are widely available and bioequivalent to brand-name versions. The 0.05 mg/day generic is the most commonly dispensed strength in U.S. menopause prescribing.

Twice-weekly vs once-weekly application schedules

Transdermal estradiol patches come in two application schedules:

Twice-weekly patches. Changed every 3-4 days (e.g., Sunday and Wednesday). Examples: Vivelle-Dot, Minivelle, Estradot. The patch matrix releases estradiol consistently over the 3-4 day window. Twice-weekly patches are smaller, tend to stay on better, and are the most common choice in current prescribing.

Once-weekly patches. Changed every 7 days. Examples: Climara, generic 7-day estradiol. The patch is larger because it must hold a 7-day reservoir. Adhesion can decrease after day 5, especially in hot weather or with frequent showering. Some patients prefer the convenience of weekly changes despite the size.

Both schedules produce similar steady-state serum estradiol levels at equivalent daily doses. The choice usually comes down to patient preference and skin tolerance. Patients with adhesion issues often do better on twice-weekly patches because the smaller surface area is easier to keep attached.

Schedule	Change frequency	Patch size	Adhesion stability
Twice-weekly	Every 3-4 days	Smaller (5-10 cm²)	Higher
Once-weekly	Every 7 days	Larger (15-25 cm²)	Lower after day 5

How to convert from oral estradiol to a patch

Oral and transdermal estradiol aren't milligram-equivalent because oral estradiol undergoes extensive first-pass metabolism in the liver. Standard equivalency:

Oral estradiol	Transdermal patch	Conjugated estrogens (oral)
0.5 mg/day	0.025 mg/day	0.3 mg/day
1 mg/day	0.05 mg/day	0.625 mg/day
2 mg/day	0.1 mg/day	1.25 mg/day

Source: NAMS 2022 Position Statement; Mayo Clinic Proceedings hormone therapy guidelines.

A patient switching from 1 mg oral estradiol to a transdermal patch typically starts at 0.05 mg/day. Some clinicians choose to step down by one strength (0.0375 mg/day) for the first 4 weeks to minimize side effects, then titrate up if symptoms recur.

The transdermal route is preferred for patients with:

• History of migraine with aura
• Elevated VTE risk (smoking, BMI over 30, age over 60, factor V Leiden)
• Hypertriglyceridemia
• Active gallbladder disease
• Liver impairment

The Canonico et al. ESTHER study (BMJ 2010) found transdermal estradiol does not increase VTE risk above baseline, while oral estradiol roughly doubles it. This is the main clinical reason for the transdermal preference in higher-risk patients.

How to convert between patch strengths

Switching between patch strengths is straightforward because all are dosed by mg per day:

Stepping up (e.g., 0.025 to 0.05 mg/day):

• Apply the new strength on the next scheduled change day.
• No tapering or overlap is needed.
• Wait 4-6 weeks at the new dose before assessing symptom response.

Stepping down (e.g., 0.075 to 0.05 mg/day):

• Apply the new strength on the next scheduled change day.
• Some patients experience temporary symptom rebound for 1-2 weeks.
• If symptoms return, the prior dose was the appropriate maintenance level.

Switching brands at the same strength:

• Direct switch with no overlap.
• Generics and brand patches at the same labeled mg/day are bioequivalent.
• Adhesion characteristics can differ between brands; some patients prefer specific formulations for skin reasons.

A handful of patients are sensitive to changes in patch matrix or adhesive. If you switch brands and develop a new skin reaction or adhesion issue, the formulation difference is usually the cause, not the estradiol itself.

Starting dose and titration schedule

The standard titration approach for new patch users:

Week	Dose	Notes
1-4	0.025 mg/day	Starting dose for mild symptoms
5-8	0.0375 mg/day	If symptoms persist after 4 weeks
9-16	0.05 mg/day	Standard maintenance dose for most patients
17+	0.075-0.1 mg/day	Reserved for severe or refractory symptoms

For severe symptoms (vasomotor episodes more than 8 per day, sleep disruption every night, surgical menopause), starting at 0.05 mg/day is reasonable. For surgical menopause in younger patients (oophorectomy under 45), 0.075 or 0.1 mg/day is often the starting dose because endogenous estradiol drops to zero overnight and the patient typically needs full physiologic replacement.

Symptom assessment is the primary titration criterion. Serum estradiol monitoring is typically not used for titration in menopausal hormone therapy because population variation is wide and clinical response is what matters. Some clinicians check serum estradiol if the patient isn't responding to a standard dose.

For more on hormone therapy and weight management considerations, see our hormones and GLP-1 therapy guide and perimenopause weight gain article.

Maximum effective dose

For most menopausal symptom management, 0.1 mg/day is the maximum standard patch dose. Going higher (combining patches, using larger patches off-label) is rarely useful because:

• Hot flash response plateaus around 0.075-0.1 mg/day for most patients.
• Higher doses increase the risk of breast tenderness, nausea, headaches, and breakthrough bleeding.
• Doses above 0.1 mg/day push serum estradiol into the high-premenopausal range, which isn't necessary for symptom relief.

Patients with primary ovarian insufficiency (POI) under age 30 sometimes need higher doses to mimic premenopausal hormone levels, especially for bone density preservation. In that population, two 0.1 mg/day patches simultaneously (delivering 0.2 mg/day) is occasionally used. This is specialized prescribing and should be guided by a reproductive endocrinologist.

For natural menopause, 0.05 mg/day is the most common maintenance dose and 0.075 mg/day is typical for patients with persistent symptoms. Reaching 0.1 mg/day is uncommon outside of surgical menopause and POI.

Patches for primary ovarian insufficiency vs natural menopause

The dosing logic differs between these two populations:

Natural menopause (typical age 45-55):

• Goal is symptom relief, not full hormone replacement.
• Starting dose 0.025-0.0375 mg/day.
• Maintenance 0.05 mg/day.
• Duration typically 5-7 years from menopause onset, individualized.

Primary ovarian insufficiency (under age 40):

• Goal is physiologic hormone replacement equivalent to premenopausal levels.
• Starting dose 0.05 mg/day, escalating to 0.075-0.1 mg/day.
• Maintenance often 0.1 mg/day or higher.
• Duration through age 50-51 (the average natural menopause age), then reassessed.

POI patients are at higher risk of osteoporosis, cardiovascular disease, and cognitive issues if undertreated. The prescribing standard is to mimic normal premenopausal estradiol exposure, not to provide minimal symptom control.

For both populations, the patient's uterus status determines progesterone need. Women with a uterus need cyclic or continuous progesterone added to estrogen therapy to prevent endometrial hyperplasia. Women without a uterus (post-hysterectomy) don't need progesterone.

Application sites and rotation

Patches are applied to clean, dry, intact skin. Standard application sites:

Approved sites:

• Lower abdomen (below the waistline)
• Buttocks
• Upper outer thigh
• Upper outer hip

Sites to avoid:

• Breasts (pharmacokinetics differ; not an FDA-approved site)
• Waistband area (clothing friction loosens adhesion)
• Recently shaved areas (alcohol from products can affect absorption)
• Skin with rashes, lotions, or recent steroid creams

Rotate sites with every patch change. Don't apply to the same exact spot more than once every 7-14 days. Rotation prevents skin irritation, which is the most common reason patients discontinue patch therapy.

After a hot shower or sauna, briefly check the patch edges. If a corner has lifted, press it firmly back. If the patch falls off completely before the next scheduled change, apply a new patch at a different site. Don't try to reattach a fallen patch with tape, as the adhesive backing won't release estradiol normally without skin contact.

When to add progesterone

Estrogen monotherapy without opposing progesterone is associated with endometrial hyperplasia and endometrial cancer in women with an intact uterus. The risk increases with both dose and duration of estrogen exposure.

Standard progesterone protocols:

Continuous combined therapy. Estrogen patch + daily oral micronized progesterone 100 mg, or a combined estrogen-progestin patch (Climara Pro, CombiPatch). This is the most common approach for postmenopausal women and produces no scheduled bleeding.

Cyclic therapy. Estrogen patch + 200 mg oral micronized progesterone for 12-14 days each month. This produces a scheduled monthly withdrawal bleed and is sometimes used in early postmenopause when patients still expect cyclic bleeding.

Levonorgestrel IUD. Progestin-releasing IUD provides endometrial protection while estrogen is delivered transdermally. Useful for women who can't tolerate oral progesterone.

The progesterone doses above are for endometrial protection, not for treatment of symptoms. Some patients use higher progesterone doses for sleep, anxiety, or vasomotor symptoms, which is a separate prescribing decision.

Women without a uterus (post-hysterectomy) don't need progesterone with estrogen patches. The risk-benefit calculation tips toward unopposed estrogen in this group.

FAQ

What's the most common starting dose for an estradiol patch? 0.025 mg/day or 0.0375 mg/day, applied twice weekly. Most providers start at the lowest effective dose and titrate up after 4-6 weeks if symptoms persist. Patients with severe symptoms or surgical menopause may start at 0.05 mg/day.

How often do you change an estradiol patch? Twice-weekly patches (Vivelle-Dot, Minivelle, Estradot) are changed every 3-4 days, usually on the same two days each week (e.g., Sunday and Wednesday). Once-weekly patches (Climara) are changed every 7 days on the same day each week.

What does 0.05 mg/day mean on a patch label? 0.05 mg/day means the patch delivers 50 mcg of estradiol through the skin every 24 hours. The total estradiol in the patch is higher (typically 4-7 mg), but only the amount needed to maintain a 50 mcg/day delivery actually reaches your bloodstream during use.

Is a 0.05 mg patch the same as 1 mg oral estradiol? Roughly equivalent in serum estradiol levels and symptom control. The transdermal route bypasses first-pass liver metabolism, which means lower triglycerides, lower VTE risk, and reduced effects on liver-produced proteins. Most clinicians prefer transdermal for patients with cardiovascular or metabolic risk factors.

Can I cut an estradiol patch in half to lower the dose? Generally no. Matrix-type patches lose their controlled-release properties when cut. Reservoir patches can leak. If you need a lower dose than 0.025 mg/day, ask your provider for a smaller-strength patch rather than cutting one. Twice-weekly patches come in strengths down to 0.025 mg/day.

What if my patch falls off? Apply a new patch at a different site. Most patches stay on better with daily morning application versus evening. If patches consistently fall off, your provider may switch you from once-weekly to twice-weekly, or to a different brand with different adhesive.

Can I shower or swim with an estradiol patch on? Yes. Patches are designed to stay on through showers, baths, and swimming. Avoid hot tubs, saunas, and prolonged hot water exposure, which can loosen adhesion. Pat dry rather than rubbing the patch area.

How long does it take for an estradiol patch to start working? Serum estradiol rises within 4-8 hours of patch application. Hot flash improvement is typically noticeable within 1-2 weeks. Full symptom benefit usually plateaus at 4-6 weeks. If you're not responding at 6 weeks, dose adjustment is appropriate.

Do I need progesterone with an estradiol patch? Yes, if you have a uterus. Estrogen alone increases the risk of endometrial hyperplasia and cancer. Standard regimens add either oral micronized progesterone, a combined patch, or a progestin-releasing IUD. Women without a uterus don't need progesterone.

Is the estradiol patch safer than oral estradiol? For VTE and stroke risk, yes. Transdermal estradiol does not increase VTE risk in observational studies, while oral estrogen roughly doubles VTE risk (Canonico et al., BMJ 2010). For other endpoints (breast cancer, cardiovascular disease), the route of administration matters less than dose, duration, and underlying risk.

Can I move my patch from one site to another between scheduled changes? No. Once applied, patches release estradiol through the skin contact area. Removing and reapplying disrupts the controlled release and can cause inconsistent serum levels. If a patch is in a problematic location, wait until the scheduled change.

Why do patches sometimes leave a sticky residue? The adhesive layer is designed to stay attached for the full wear period. Some residue at removal is normal. Baby oil, mineral oil, or rubbing alcohol on a cotton ball usually removes residue. Don't scrub the area, as it can cause irritation that affects the next patch's adhesion.

Sources

1. The North American Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause. 2022;29:767-794.
2. Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of administration and progestogens (ESTHER study). BMJ. 2010;340:c1333.
3. Stuenkel CA, et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:3975-4011.
4. Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality (Women's Health Initiative). JAMA. 2017;318:927-938.
5. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013;121:1407-1410.
6. Notelovitz M. Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause. MedGenMed. 2006;8:85.
7. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13:220-231.
8. Liu B, et al. Patterns and persistence of hormone therapy among postmenopausal women. Menopause. 2014;21:917-923.
9. Cobin RH, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause-2017 Update. Endocr Pract. 2017;23:869-880.
10. FDA. Vivelle-Dot, Climara, and Minivelle prescribing information. Accessed 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Vivelle-Dot, Minivelle, Climara, Climara Pro, Estradot, and CombiPatch are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.